At EpiDisease SL, we focus on advancing public health through innovative digital solutions and epidemiological research. Our team is dedicated to providing cutting-edge tools and insights that help organizations understand and combat disease outbreaks effectively. By leveraging data analytics and technology, we empower stakeholders to make informed decisions that enhance community health outcomes. We are committed to fostering collaboration and sharing knowledge to navigate the challenges of global health together.
First precision IVD portfolio for AIS: saliva-based genetic risk test (ScoliGEN, LDT available) + AI Cobb angle tool (ScoliVIEW, ICC 0.97). CE-IVD 2026. $1.7B TAM, no competitors. Seeking out-licensing & distribution partners.